Skip to main content
Journal cover image

Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.

Publication ,  Journal Article
Jicha, GA; Abner, EL; Arnold, SE; Carrillo, MC; Dodge, HH; Edland, SD; Fargo, KN; Feldman, HH; Goldstein, LB; Hendrix, J; Peters, R; Weber, CJ ...
Published in: Alzheimers Dement
June 2022

BACKGROUND: Consensus guidance for the development and identification of high-quality Alzheimer's disease clinical trials is needed for protocol development and conduct of clinical trials. METHODS: An ad hoc consensus committee was convened in conjunction with the Alzheimer's Association to develop consensus recommendations. RESULTS: Consensus was readily reached for the need to provide scientific justification, registration of trials, institutional review board oversight, conflict of interest disclosure, funding source disclosure, defined trial population, recruitment resources, definition of the intervention, specification of trial duration, appropriate payment for participant engagement, risk-benefit disclosure as part of the consent process, and the requirement to disseminate and/or publish trial results even if the study is negative. CONCLUSIONS: This consensus guidance should prove useful for the protocol development and conduct of clinical trials, and may further provide a platform for the development of education materials that may help guide appropriate clinical trial participation decisions for potential trial participants and the general public.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Alzheimers Dement

DOI

EISSN

1552-5279

Publication Date

June 2022

Volume

18

Issue

6

Start / End Page

1109 / 1118

Location

United States

Related Subject Headings

  • Research Design
  • Humans
  • Geriatrics
  • Ethics Committees, Research
  • Disclosure
  • Consensus
  • Alzheimer Disease
  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jicha, G. A., Abner, E. L., Arnold, S. E., Carrillo, M. C., Dodge, H. H., Edland, S. D., … Clinical Trial Advancement & Methodology Professional Interest Area of the International Society to Advance Alzheimer’s Research and Treatment (ISTAART), . (2022). Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimers Dement, 18(6), 1109–1118. https://doi.org/10.1002/alz.12461
Jicha, Greg A., Erin L. Abner, Steven E. Arnold, Maria C. Carrillo, Hiroko H. Dodge, Steven D. Edland, Keith N. Fargo, et al. “Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.Alzheimers Dement 18, no. 6 (June 2022): 1109–18. https://doi.org/10.1002/alz.12461.
Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, et al. Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimers Dement. 2022 Jun;18(6):1109–18.
Jicha, Greg A., et al. “Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.Alzheimers Dement, vol. 18, no. 6, June 2022, pp. 1109–18. Pubmed, doi:10.1002/alz.12461.
Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJ, Clinical Trial Advancement & Methodology Professional Interest Area of the International Society to Advance Alzheimer’s Research and Treatment (ISTAART). Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimers Dement. 2022 Jun;18(6):1109–1118.
Journal cover image

Published In

Alzheimers Dement

DOI

EISSN

1552-5279

Publication Date

June 2022

Volume

18

Issue

6

Start / End Page

1109 / 1118

Location

United States

Related Subject Headings

  • Research Design
  • Humans
  • Geriatrics
  • Ethics Committees, Research
  • Disclosure
  • Consensus
  • Alzheimer Disease
  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences